The U.S. Food and Drug Administration (FDA) recently held a Patient Engagement Advisory Committee meeting focused on clinical trial informed ...

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025Reiterate cash runway into mid-2026; Q3 2024 ending ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

Suvoda, a global clinical trial technology company specializing in complex studies in therapeutic areas like oncology, ...

James Quinlan joins Cooper Levenson, enhancing its litigation team with decades of expertise in corporate law, complex ...

SEOUL, South Korea, Nov. 14, 2024 /PRNewswire/ -- Floatic, a leading AMR solutions provider for e-commerce warehouses, today announced the successful completion of its trial test with LogisALL ...

President-elect Donald Trump spoke publicly for the first time since winning the White House at the America First Policy ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

The Committee against Torture this morning held a high-level event to commemorate the fortieth anniversary of the Convention against Torture and Other ...

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...

U.S. president-elect Donald Trump's promise to slap an across-the-board tariff of at least 10 per cent on all imports ...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung ...